Researched and fact-checked in-house against primary literature and regulator records. Not reviewed by a named clinician — how we work.
Evidence-rated reference Updated August 2026
We sell nothing. No vendor sponsorship. Editorial policy
pepteyes .com

Sermorelin vs Somatropin (recombinant hGH)

Stimulating your own growth hormone versus replacing it outright.

The distinction that mattersSermorelin stimulates your pituitary to release its own GH and preserves feedback control. Somatropin replaces GH directly, suppresses endogenous secretion, and carries the full acromegaly-like side effect profile.

These are not equivalent in evidence Somatropin (recombinant hGH) is rated 5/5 and Sermorelin is rated 3/5 — a gap of 2 levels on our scale. Similar marketing does not mean similar proof.

Sermorelin Limited ApprovalSomatropin (recombinant hGH) FDA Approved
Evidence rating
3/5 Moderate Evidence rating 3 out of 5: Moderate
5/5 Very strong Evidence rating 5 out of 5: Very strong
Regulatory statusFormerly FDA-approved (Geref) as a pediatric GH diagnostic; withdrawn from the US market in 2008. Now supplied through compounding pharmacies.FDA-approved for growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, short bowel syndrome and several other indications. Distribution for anti-aging use is specifically prohibited by US federal law.
CategoryGrowth Hormone AxisGrowth Hormone Axis
Drug classTruncated GHRH analog — first 29 amino acids of human GHRH191-amino-acid recombinant human growth hormone — a protein, not a short peptide
RouteSubcutaneous, typically at nightSubcutaneous, daily (or weekly for long-acting analogs)
Half-life~10–20 minutes~3–4 hours subcutaneously
Studied inHistoric pediatric GH-deficiency diagnosis and treatment studies; small older trials in adults; extensive uncontrolled clinical use.Decades of randomized trials across pediatric and adult deficiency states; large post-marketing safety registries such as KIGS and NordiNet.
Who should avoid it
  • Active malignancy
  • Pregnancy
  • Untreated diabetes (relative)
  • Known hypersensitivity
  • Active malignancy
  • Acute critical illness — a trial in ICU patients found increased mortality
  • Proliferative diabetic retinopathy
  • Closed epiphyses when used for height
  • Anti-aging or performance use
Legal statusNo longer an approved US drug product; lawful access is via patient-specific compounding under a prescription. FDA has scrutinised this category closely.Prescription drug. US federal law (21 U.S.C. § 333(e)) prohibits distribution for any use other than approved indications, making anti-aging distribution a criminal offence.

Benefits — Sermorelin

  • Physiological GH pulses

    Raises GH without the flat supraphysiologic levels of injected recombinant GH, preserving feedback regulation.

  • Documented efficacy in GH-deficient children

    Older controlled data support growth velocity improvement in true deficiency.

  • Well tolerated in short-term use

    Decades of clinical use with a mild side-effect profile.

  • Low risk of pituitary suppression

    Unlike exogenous GH, it does not shut down the endogenous axis.

  • Reported sleep and recovery improvement

    Commonly described by users; largely uncontrolled data, plausible given GH secretion is sleep-linked.

Benefits — Somatropin (recombinant hGH)

  • Restores growth in deficient children

    Unambiguous, dose-dependent improvement in growth velocity and final adult height — the indication it was developed for.

  • Body composition in adult deficiency

    Reduces fat mass and increases lean mass in genuine adult GH deficiency, with improved quality-of-life scores.

  • Bone density improvement

    Increases bone mineral density over multi-year treatment in deficient adults.

  • Multiple rare disease indications

    Turner syndrome, Prader-Willi syndrome, SHOX deficiency and others, each with dedicated trial evidence.

Risks & cons — Sermorelin

  • Weak evidence for adult anti-aging use

    The body-composition, energy and longevity claims made in wellness clinics have not been tested in adequate randomized trials.

  • Very short half-life

    Requires frequent dosing and produces only a transient signal.

  • Glucose intolerance with sustained GH elevation

    A class effect of raising the GH/IGF-1 axis.

  • Injection-site reactions and flushing

    Common and generally minor.

  • Compounding variability

    Potency and sterility depend entirely on the compounding pharmacy; product quality is not uniform.

Risks & cons — Somatropin (recombinant hGH)

  • Distributing it for anti-aging is a federal crime in the US

    GH is unusual: federal law restricts distribution to approved indications specifically, and prosecutions of anti-aging clinics have followed. This is not a grey area.

  • Insulin resistance and diabetes

    GH is directly counter-regulatory to insulin. New-onset type 2 diabetes is a recognised consequence of sustained therapy.

  • Fluid retention, arthralgia and carpal tunnel

    Dose-related and common in adults, sometimes limiting treatment.

  • Intracranial hypertension

    Uncommon but serious; presents with headache and visual change and requires prompt assessment.

  • Slipped capital femoral epiphysis in children

    A recognised orthopedic complication requiring surveillance during pediatric treatment.

Infographic for Sermorelin
Infographic for Somatropin (recombinant hGH)

A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.